The HCFC1R1 Knockout NCI-H1299 Polyclonal Cells are a CRISPR/Cas9-mediated gene disruption product comprising a polyclonal population of NCI-H1299 cells deficient in HCFC1R1. This format yields a heterogeneous mixture of edited alleles, reducing clonal artifacts and enabling robust loss-of-function analysis. The knockout cells are designed to study the role of HCFC1R1 in cell cycle control and transcriptional regulation within a lung adenocarcinoma context.
The NCI-H1299 host cell line is derived from a lymph node metastasis of human lung adenocarcinoma and is p53-deficient, abrogating critical tumor-suppressive checkpoints. Widely used in non-small cell lung cancer research, NCI-H1299 cells serve as a model for investigating tumorigenesis, metastatic dissemination, and therapeutic sensitivity. Their epithelial features and stable growth characteristics make them an essential platform for oncogenic mechanism studies.
HCFC1R1 is a regulator of HCFC1, a transcriptional coactivator that promotes expression of cell cycle genes through E2F transcription factors. HCFC1R1 directly binds HCFC1 and inhibits its chromatin association, thereby repressing transcription of targets such as CCNA2 and CCNB1. This mechanism involves corepressor complexes containing SIN3A and HDAC1/2, as well as THAP domain proteins. Consequently, HCFC1R1 acts as a brake on HCFC1-driven proliferation signals, integrating inputs from upstream growth factor pathways and cell cycle-dependent transcriptional cues.
In p53-null NCI-H1299 cells, where cell cycle checkpoints are inherently impaired, HCFC1R1 knockout likely amplifies dysregulation by releasing HCFC1 to transactivate cyclin D1, CDK4, and additional E2F targets. This model allows interrogation of the HCFC1/HCFC1R1 balance independent of p53-mediated controls, providing insight into compensatory oncogenic pathways. Given the cell line’s derivation from a lung adenocarcinoma lymph node metastasis, the knockout cells are also pertinent for invasion and migration studies.
These knockout cells are suited for a variety of applications including immunoblotting for HCFC1R1 and HCFC1 abundance, RT-qPCR quantification of E2F-responsive genes, and co-immunoprecipitation to assess HCFC1R1-HCFC1 complex formation. Proliferative phenotypes can be measured via MTT, BrdU incorporation, and colony formation, while cell cycle distribution is analyzed by flow cytometry. Drug response profiling, for instance cisplatin sensitivity, can be conducted to explore therapeutic vulnerabilities. RNA-seq enables genome-wide transcriptome analysis. The model offers a versatile platform for deciphering the HCFC1/HCFC1R1 axis in NSCLC. For additional details, contact Ascent Research.
